Company recalls weight loss supplements

A South Florida company is voluntarily recalling weight loss supplements called "JaDera" and "Xiyouji Qingzhi."

Florida Dolphin Intertrade Corp. announced Friday that these products have been found to contain undeclared Sibutramine, which was a previously approved controlled substance for the treatment of obesity. It was removed from the U.S. market in October 2010 for safety reasons.

Florida Dolphin Intertrade says that products containing Sibutramine are known to substantially increase blood pressure and pulse rate in some patients and may present a significant risk for patients with a history of , , arrhythmias or stroke. These products may also interact in life threatening ways with other medications a consumer may be taking.

The supplements were distributed from May 2011 to May 2013.

Consumers with questions regarding this recall can contact 305-383-7600

not rated yet
add to favorites email to friend print save as pdf

Related Stories

FDA seizes illegal dietary supplements in Florida

Feb 14, 2013

(AP)—The Food and Drug Administration says U.S. marshals have seized illegal dietary supplements from a Florida company because some may contain a dangerous pharmaceutical ingredient.

Fla. compounding pharmacy recalls sterile drugs

Apr 21, 2013

A Florida-based compounding pharmacy is voluntarily recalling all lots of its sterile non-expired drug products sold nationwide over concerns the products are not sterile and may contain bacteria.

Farm Rich products recalled over E. coli fears

Mar 29, 2013

(AP)—Rich Products Corp. has announced a voluntary recall of its Farm Rich Mini Quesadillas and other Farm Rich products because of a possible contamination with E. coli bacteria.

Recommended for you

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

User comments